LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Schimanski, Carl C ^a   Möhler, Markus ^a   Schön, Michael ^b   van Cutsem, Eric ^c   Greil, Richard ^d   Bechstein, Wolf O ^e   Hegewisch Becker, Susanna ^f   von Wichert, Götz ^g   Vöhringer, Matthias ^h   Heike, Michael ⁱ   Heinemann, Volker ^j   Peeters, Marc ^k   Kanzler, Stephan ^l   Kasper, Stefan ^m   Overkamp, Friedrich ⁿ   Schröder, Jan ^o   Seehofer, Daniel ^p   Kullmann, Frank ^q   Linz, Bernhard ^r   Schmidtmann, Irene ^a   Smith Machnow, Victoria ^s   Gockel, Ines ^a   Lang, Hauke ^a   Galle, Peter R ^a   more..

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Municipal Hospital Karlsruhe   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d University Hospital of Salzburg   (Austria)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Onkologische Schwerpunktpraxis Eppendorf   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h ROBERT BOSCH HOSPITAL   (Germany)

ⁱ Hospital of Dortmund   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^l Leopoldina Hospital   (Germany)

^m UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁿ Oncologianova GmbH   (Germany)

^o Outpatient center for hematology and oncology ^*  (Germany)

^p HUMBOLDT UNIVERSITY   (Germany)

^q Kliniken Nordoberpfalz AG   (Germany)

^r Outpatient center for hematology and oncology   (Germany)

^s iOMEDICO   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EMEPEPIMUT S; MUCIN 1; PLACEBO; SODIUM CHLORIDE; CANCER VACCINE; L BLP25; L-BLP25; MEMBRANE PROTEIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION; ADENOCARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 84859514198     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-144     Document Type: Article

References (39)

1. Powell E, Chow LQ. BLP-25 liposomal vaccine: a promising potential therapy in non-small cell lung cancer. Expert Rev Resp Med 2008, 2(1):37-45.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33. 10.3322/canjclin.50.1.7, 10735013.
3. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003, 95:1276-1299. 10.1093/jnci/djg040, 12953083.
4. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984, 3:303-324. 10.1007/BF00051457, 6394125.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767. 10.1016/0092-8674(90)90186-I, 2188735.
6. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992, 70:1727-1731. 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P, 1516027.
7. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993, 9:138-141. 10.1016/0168-9525(93)90209-Z, 8516849.
8. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002, 99:9433-9438. 10.1073/pnas.122612899, 123158, 12093899.
9. Schmiegel W, Pox C, Reinacher-Schick A, et al. S3 guidelines for colorectal cancer. Z Gastroenterol 2010, 48:65-136. 10.1055/s-0028-1109936, 20072998.
10. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005, 23:2038-2048. 10.1200/JCO.2005.00.349, 15774795.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
12. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007, 11:1057-1077. 10.1007/s11605-006-0061-3, 17530336.
13. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003, 46:S22-S31.
14. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
15. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250:440-448.
16. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005, 23:7125-7134. 10.1200/JCO.2005.08.722, 16192596.
17. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. discussion 18-21, 10.1097/00000658-199909000-00004, 1420876, 10493478.
18. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 1999, 59:5169-1575.
19. Linnemann U, Schimanski CC, Gebhardt C, Berger MR. Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int J Colorectal Dis 2004, 19:380-386. 10.1007/s00384-003-0555-3, 14634776.
20. Schimanski CC, Linnemann U, Arbogast R, Berger MR. Extended staging results from the detection of isolated tumor cells in the liver of colorectal cancer patients. Oncol Rep 2001, 8:185-188.
21. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26:4906-4911. 10.1200/JCO.2008.17.3781, 18794541.
22. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006, 24:4976-4982. 10.1200/JCO.2006.06.8353, 17075115.
23. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007, 204:753-761. discussion 61-63, 10.1016/j.jamcollsurg.2006.12.036, 17481478.
24. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016. 10.1016/S0140-6736(08)60455-9, 2277487, 18358928.
25. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003, 64:131-138. 10.1159/000067772, 12566910.
26. Lorenz M, Muller HH, Staib-Sebler E, et al. Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma. Langenbecks Arch Surg 1999, 384:328-338. 10.1007/s004230050210, 10473852.
27. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003, 22:6107-6110. 10.1038/sj.onc.1206732, 12955090.
28. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163-175. 10.1016/S1535-6108(04)00020-0, 14998492.
29. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993, 53:641-651.
30. Zotter S, Hageman PC, Lossnitzer A. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Reviews 1988, 11:55-101.
31. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998, 4:43-49. 10.1038/nm0198-043, 9427605.
32. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996, 7:565-577. 275910, 8730100.
33. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995, 129:255-65. 10.1083/jcb.129.1.255, 2120361, 7698991.
34. Suzuki H, Shoda J, Kawamoto T, et al. Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin Exp Metastasis 2004, 21:321-329.
35. Zhang K, Tang W, Qu X, et al. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology 2009, 56:960-963.
36. Schimanski CC, Linnemann U, Galle PR, Arbogast R, Berger MR. Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications. Int J Oncol 2003, 23:791-796.
37. Schimanski CC, Mohler M, Zimmermann T, et al. Detection of hepatic micrometastases in the context of adjuvant chemotherapy and surgery for hepatic metastases. Dtsch Med Wochenschr 2010, 135:1078-1082. 10.1055/s-0030-1253703, 20486059.
38. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681. 10.1200/JCO.2005.13.011, 16170175.
39. Thatcher N, Heighway J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 2011, 15:1034-1042.